Shoeb Hussain, MD
Advanced Heart Failure and Transplant Cardiology · Park Ridge, ILNPI 1184990673
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. E.r. Squibb & Sons, L.L.C. accounts for 92.0% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2023 at $14,344 and has fallen 96.3% since, to $537 in 2025.
Across 80 payments — averaging $211.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$16K
- Abbott$475
- Johnson & Johnson$178
- Shockwave Medical, Inc$155
- Boston Scientific$90
- United Therapeutics Corporation$88
- plus $374 from 10 others
Across 2 payments — averaging $16,363 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$33K
What the payments were for
- Consulting fees$4,50027%
- Speaking & faculty fees$8,33349%
- Travel & lodging$1,71810%
- Food & beverage$2,38414%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 40 | $15,574 |
| Abbott | 12 | $475 |
| Johnson & Johnson | 7 | $178 |
| Shockwave Medical, Inc | 1 | $155 |
| Boston Scientific | 4 | $90 |
| United Therapeutics Corporation | 1 | $88 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $76 |
| Cvrx, Inc. | 2 | $58 |
| Pfizer | 2 | $52 |
| Biosense Webster, Inc. | 1 | $44 |
| Bayer | 1 | $35 |
| Actelion Pharmaceuticals US, Inc. | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Heartflow, Inc. | 1 | $20 |
| AstraZeneca | 1 | $20 |
| Philips North America LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,934 in reported general payments places this provider in the 55th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.
See all advanced heart failure and transplant cardiology providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 68 | $1,638,720 |
| OpsumitMacitentan | 57 | $727,341 |
| Tyvaso DpiTreprostinil | 14 | $361,694 |
| EntrestoSacubitril/Valsartan | 214 | $297,352 |
| AdempasRiociguat | 21 | $291,093 |
| EliquisApixaban | 192 | $241,332 |
| JardianceEmpagliflozin | 151 | $218,548 |
| CamzyosMavacamten | 21 | $158,088 |
| XareltoRivaroxaban | 37 | $44,538 |
| FarxigaDapagliflozin Propanediol | 17 | $23,927 |
| Bumetanide | 327 | $10,993 |
| Sildenafil Citrate | 22 | $6,922 |
| Klor-ConPotassium Chloride | 26 | $6,799 |
| Metoprolol Succinate | 321 | $5,497 |
| Torsemide | 121 | $2,641 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $52 | $1,880,052260 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $27 | $727,34157 claims |
| BayerAdempas | $35 | $291,09321 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $15,574 | $158,08821 claims |
| Johnson & JohnsonXarelto | $178 | $44,53837 claims |
| AstraZenecaFarxiga | $20 | $23,92717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.
Other advanced heart failure and transplant cardiology in Park Ridge
- Ibrahim ShaikPark Ridge$15K
- Maria Rosa CostanzoNaperville$716K
- Jonathan RichChicago$327K
- Esther VorovichChicago$224K
- Jane WilcoxChicago$220K
- Ali ValikaElmhurst$218K
- Manreet KanwarChicago$162K
- Jonathan GrinsteinChicago$128K
- Muhyaldee DiaOak Lawn$125K
- Bow ChungChicago$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.